De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Amedisys Beheer

Beheer criteriumcontroles 1/4

De CEO Amedisys' is Richard Ashworth, benoemd in Apr2023, heeft een ambtstermijn van 1.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 16.97M, bestaande uit 4.1% salaris en 95.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.088% van de aandelen van het bedrijf, ter waarde $ 2.78M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.8 jaar en 4.9 jaar.

Belangrijke informatie

Richard Ashworth

Algemeen directeur

US$17.0m

Totale compensatie

Percentage CEO-salaris	4.1%
Dienstverband CEO	1.5yrs
Eigendom CEO	0.09%
Management gemiddelde ambtstermijn	1.8yrs
Gemiddelde ambtstermijn bestuur	4.9yrs

Recente managementupdates

Recent updates

An Intrinsic Calculation For Amedisys, Inc. (NASDAQ:AMED) Suggests It's 38% Undervalued

Sep 04

Amedisys: ROIC, Tangible Book Value Each Softening

Aug 24

Slowing Rates Of Return At Amedisys (NASDAQ:AMED) Leave Little Room For Excitement

Aug 04

Amedisys profit beats by $0.24, revenue misses by $25.23M, 2022 guidance below estimates

Jul 27

We Think Amedisys (NASDAQ:AMED) Can Stay On Top Of Its Debt

Jul 20

At US$115, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

Jun 04

Returns On Capital At Amedisys (NASDAQ:AMED) Have Stalled

May 05

Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 40% Discount?

Apr 20

Does Amedisys (NASDAQ:AMED) Deserve A Spot On Your Watchlist?

Apr 06

Is Amedisys (NASDAQ:AMED) A Risky Investment?

Feb 20

Amedisys (NASDAQ:AMED) Shareholders Will Want The ROCE Trajectory To Continue

Jan 19

Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

Dec 03

These 4 Measures Indicate That Amedisys (NASDAQ:AMED) Is Using Debt Safely

Nov 18

Amedisys (NASDAQ:AMED) Could Easily Take On More Debt

Aug 18

Calculating The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Jul 23

Amedisys: Strategic Contessa Acquisition Underpins The Home Healthcare Growth Opportunity

Jul 18

Under The Bonnet, Amedisys' (NASDAQ:AMED) Returns Look Impressive

Jun 28

It Looks Like Shareholders Would Probably Approve Amedisys, Inc.'s (NASDAQ:AMED) CEO Compensation Package

Jun 02

Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

May 24

Analyse CEO-vergoeding

Hoe is Richard Ashworth's beloning veranderd ten opzichte van Amedisys's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	US$92m
Mar 31 2024	n/a	n/a	-US$21m
Dec 31 2023	US$17m	US$692k	-US$10m

Compensatie versus markt: De totale vergoeding ($USD 16.97M ) Richard } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.79M ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Richard te vergelijken met de prestaties van het bedrijf.

CEO

Richard Ashworth (49 yo)

1.5yrs

Tenure

US$16,974,025

Compensatie

Mr. Richard M. Ashworth served as Director at Tivity Health, Inc. since June 1, 2020 until April 2023 and had been its President since June 1, 2020 and served as its Chief Executive Officer since June 1, 2...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Richard Ashworth	President	1.5yrs	US$16.97m	0.088% $ 2.8m
Scott Ginn	Executive VP	7yrs	US$4.45m	0.077% $ 2.4m
Denise Bohnert	Chief Compliance Officer	5.1yrs	US$1.28m	geen gegevens
Nick Muscato	Chief Strategy Officer	no data	US$1.37m	0.0065% $ 204.2k
Allyson Guidroz	Chief Accounting Officer & Principal Accounting Officer	1.2yrs	geen gegevens	0.0097% $ 303.8k
Pete Hartley	CTO & Senior VP of Business Operations Systems	no data	geen gegevens	geen gegevens
Jennifer Griffin	Senior VP	2yrs	geen gegevens	geen gegevens
Kendra Kimmons	VP of Marketing & Communications & Media Relations	no data	geen gegevens	geen gegevens
Caitlin Franklin	Acting Chief People Officer	less than a year	geen gegevens	geen gegevens
Francis Mayer	Senior Vice President of Development	no data	geen gegevens	geen gegevens

1.8yrs

Gemiddelde duur

47.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van AMED wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Richard Ashworth	President	1.5yrs	US$16.97m	0.088% $ 2.8m
Paul Kusserow	Chairman	9.8yrs	US$4.00m	1.33% $ 41.9m
Bruce Perkins	Independent Director	9.5yrs	US$267.62k	0.063% $ 2.0m
Vickie Capps	Independent Director	4.9yrs	US$277.62k	0.020% $ 618.9k
Molly Coye	Independent Director	4.9yrs	US$267.62k	0.017% $ 523.1k
Julie Klapstein	Lead Independent DIrector	8.5yrs	US$282.62k	0.039% $ 1.2m
Jeffrey Rideout	Independent Director	8.5yrs	US$267.62k	0.018% $ 572.7k
Teresa Kline	Independent Director	4.9yrs	US$272.62k	0.020% $ 618.9k
Ivanetta Samuels	Independent Director	3.8yrs	US$252.62k	0.013% $ 406.2k

4.9yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van AMED wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.9 jaar).

Amedisys Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Michael P. North Leaves Amedisys, Inc. as Chief Information Officer and Compensation Committee of the Board of Directors, Effective August 31, 2024

Insufficient new directors

President notifies of intention to sell stock

Chairman & CEO exercised options and sold US$221k worth of stock

Insufficient new directors

Amedisys, Inc. Names Scott Ginn as Acting Chief Operating Officer

Recent updates

Michael P. North Leaves Amedisys, Inc. as Chief Information Officer and Compensation Committee of the Board of Directors, Effective August 31, 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2024 earnings: EPS misses analyst expectations

Full year 2023 earnings: EPS misses analyst expectations

Insufficient new directors

President notifies of intention to sell stock

Consensus EPS estimates fall by 54%

Third quarter 2023 earnings: EPS misses analyst expectations

Option Care Health, Inc. (NasdaqGS:OPCH) cancelled the acquisition of Amedisys, Inc. (NasdaqGS:AMED).

Investor sentiment improves as stock rises 19%

Option Care Health, Inc. (NasdaqGS:OPCH) entered into an agreement and plan of merger to acquire Amedisys, Inc. (NasdaqGS:AMED) for $3.2 billion.

Price target decreased by 8.5% to US$98.85

Option Care Health, Inc. (NasdaqGS:OPCH) entered into an agreement and plan of merger to acquire Amedisys, Inc. (NasdaqGS:AMED) for $3.2 billion.

Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 41% Discount?

Does Amedisys (NASDAQ:AMED) Have A Healthy Balance Sheet?

Full year 2022 earnings: EPS exceeds analyst expectations

Amedisys, Inc. (NasdaqGS:AMED) announces an Equity Buyback for $100 million worth of its shares.

Amedisys (NASDAQ:AMED) Will Be Hoping To Turn Its Returns On Capital Around

Chairman & CEO exercised options and sold US$221k worth of stock

Amedisys, Inc. to Report Q4, 2022 Results on Feb 15, 2023

At US$83.54, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

A Look At The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Insufficient new directors

Amedisys, Inc. Names Scott Ginn as Acting Chief Operating Officer

Amedisys, Inc. Announces CEO Changes

High number of new directors

Capital Allocation Trends At Amedisys (NASDAQ:AMED) Aren't Ideal

Consensus EPS estimates fall by 16%

Price target decreased to US$126

Amedisys, Inc. Provides Earnings Guidance for the Year 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Amedisys, Inc. to Report Q3, 2022 Results on Oct 26, 2022

Amedisys, Inc. Announces Resignation of David L. Kemmerly as Chief Legal and Government Affairs Officer

Is Now The Time To Look At Buying Amedisys, Inc. (NASDAQ:AMED)?

An Intrinsic Calculation For Amedisys, Inc. (NASDAQ:AMED) Suggests It's 38% Undervalued

Amedisys: ROIC, Tangible Book Value Each Softening

Consensus EPS estimates fall by 11%

Slowing Rates Of Return At Amedisys (NASDAQ:AMED) Leave Little Room For Excitement

Price target decreased to US$145

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Amedisys profit beats by $0.24, revenue misses by $25.23M, 2022 guidance below estimates

We Think Amedisys (NASDAQ:AMED) Can Stay On Top Of Its Debt

Price target decreased to US$160

Amedisys, Inc. to Report Q2, 2022 Results on Jul 27, 2022

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 1000 Growth-Defensive Index

At US$115, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

Price target decreased to US$174

Returns On Capital At Amedisys (NASDAQ:AMED) Have Stalled

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors

Amedisys, Inc. Announces Promotion of Nick Muscato as Chief Strategy Officer

Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 40% Discount?

Amedisys, Inc. to Report Q1, 2022 Results on Apr 27, 2022

Does Amedisys (NASDAQ:AMED) Deserve A Spot On Your Watchlist?

Amedisys, Inc. (NasdaqGS:AMED) completed the acquisition of Assets of AssistedCare Home Health, Inc. and RH Homecare Services, LLC.

Amedisys, Inc. Announces Resignation of Richard A. Lechleiter from the Board of Directors

Investor sentiment improved over the past week

Price target decreased to US$184

Chairman & CEO exercised options and sold US$2.8m worth of stock

Full year 2021 earnings: EPS misses analyst expectations

Amedisys, Inc. (NasdaqGS:AMED) signed a definitive agreement to acquire Assets of AssistedCare Home Health, Inc.

Is Amedisys (NASDAQ:AMED) A Risky Investment?

Amedisys, Inc. (NasdaqGS : AMED) agreed to acquire Evolution Health, LLC from Emergency Medical Services LP Corporation.

Amedisys, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Amedisys (NASDAQ:AMED) Shareholders Will Want The ROCE Trajectory To Continue

High number of new directors

Investor sentiment improved over the past week

Lead Independent Director recently bought US$141k worth of stock

Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?